Tirbanibulin ointment 1%

DRUG4 trials

Sponsors

Almirall, S.A., Austin Institute for Clinical Research, The Skin Center Dermatology Group, Bruce Robinson, MD

Conditions

Basal Cell CarcinomasKeratinocyte CarcinomaKeratosis, ActinicSkin CancerSquamous Cell CarcinomaSuperficial Basal Cell CarcinomaWarts Hand

Phase 1

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

RecruitingNCT07010692

Bruce Robinson, MDBasal Cell Carcinomas, Keratinocyte Carcinoma, Skin Cancer +1

Start: 2025-05-16End: 2030-06-30Target: 100Updated: 2025-09-17

Phase 2

Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

CompletedNCT05713760

Austin Institute for Clinical ResearchSuperficial Basal Cell Carcinoma

Start: 2023-04-17End: 2024-03-07Updated: 2024-07-19

Phase 3

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

CompletedNCT05279131

Almirall, S.A.Keratosis, Actinic

Start: 2022-06-28End: 2022-12-28Updated: 2024-01-23

Phase 4

Tirbanibulin for Pediatric Warts

RecruitingNCT06791525

The Skin Center Dermatology GroupWarts Hand

Start: 2025-05-01End: 2026-12-30Target: 10Updated: 2026-04-23

Related Papers

Safety, Tolerability and Efficacy of Tirbanibulin Ointment 1% Treatment on 100 cm2 of the Face and Scalp in Patients with Actinic Keratosis: A Phase 3 Study

SKIN The Journal of Cutaneous Medicine2023-11-13